One-year data from Visioneering Technologies’ (VTI) Protect study has demonstrated the safety and effectiveness of its Naturalvue multifocal contact lenses for myopia progression in children.
Presented at the American Academy of Optometry’s annual meeting in New Orleans, the multicentre, randomised, double-masked, controlled trial data corroborates Naturalvue’s real-world data analyses, said Dr Ashley Tuan, VTI’s chief medical officer. “Based on a preliminary analysis of the one-year follow-up, the treatment effect was 0.41D, or 69% for refractive error, versus the control group. For axial length, the treatment effect was 0.17mm, or 59%, versus the control group. Combined with the six-year data previously published in Clinical Ophthalmology in 2022 and analyses from two other independent studies released in September 2023, these preliminary one-year data confirm that Naturalvue multifocal effectively manages eye growth and refractive error change among progressing myopic children.”
Discussing the data at CCLS NZ 2024 on the CLC stand, Dr Emma Gillies said the data release was exciting as optometrists can now have real confidence in the impact of Naturalvue lenses on myopia control. “We have multiple data now we can give to practitioners to know they are making the right choice for kids.”
The Protect study is ongoing and more data should be released at the end of this year, she said.
